Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials

Massari, Francesco; Rizzo, Alessandro; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Ardizzoni, Andrea; Santoni, Matteo

doi:10.1016/j.ejca.2021.06.015

Cited by 78 publications

(47 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past few years, ICIs plus TKIs have made a major breakthrough in the treatment of mRCC patients. 3 , 18 , 40 Comparison with the sunitinib group, a higher proportion of grade 3–4 diarrhea and grade 3–4 decreased appetite occurred in patients treated with immuno-TKI combinations in a meta-analysis. 19 There remains a critical need to better predict treatment responses in patients with mRCC and to pre-emptively recognize patients at higher risk of treatment-attributable toxicities.…”

Section: Discussionmentioning

confidence: 99%

Gut Microbiota and Sunitinib-Induced Diarrhea in Metastatic Renal Cell Carcinoma: A Pilot Study

Su¹,

Lu²,

Chen³

et al. 2021

CMAR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Gut Microbiota and Sunitinib-Induced Diarrhea in Metastatic Renal Cell Carcinoma: A Pilot Study

Su¹,

Lu²,

Chen³

et al. 2021

CMAR

View full text Add to dashboard Cite

“…However, different pathologic types of RCC have different prognosis. In recent years, the application of immune checkpoint inhibitors has been significantly beneficial in metastatic RCC ( 10 , 11 ). And the magnitude of benefit of the immune checkpoint inhibitors-tyrosine kinase inhibitors combination over sunitinib monotherapy in treatment-naïve metastatic RCC patients is consistent across the clinicopathological subgroups ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundRenal cell carcinoma (RCC) is the most common type of kidney cancer. Studying the pathogenesis of RCC is particularly important, because it could provide a direct guide for clinical treatment. Given that tumor heterogeneity is probably reflected at the mRNA level, the study of mRNA in RCC may reveal some potential tumor-specific markers, especially single-cell RNA sequencing (scRNA-seq).MethodsWe performed an exploratory study on three pathological types of RCC with a small sample size. This study presented clear-cell RCC (ccRCC), type 2 pRCC, and chRCC in a total of 30,263 high-quality single-cell transcriptome information from three pathological types of RCC. In addition, scRNA-seq was performed on normal kidneys. Tumor characteristics were well identified by the comparison between different pathological types of RCC and normal kidneys at the scRNA level.ResultsSome new tumor-specific markers for different pathologic types of RCC, such as SPOCK1, PTGIS, REG1A, CP and SPAG4 were identified and validated. We also discovered that NDUFA4L2 both highly expressed in tumor cells of ccRCC and type 2 pRCC. The presence of two different types of endothelial cells in ccRCC and type 2 pRCC was also identified and verified. An endothelial cell in ccRCC may be associated with fibroblasts and significantly expressed fibroblast markers, such as POSTN and COL3A1. At last, by applying scRNA-seq results, the activation of drug target pathways and sensitivity to drug responses was predicted in different pathological types of RCC.ConclusionsTaken together, these findings considerably enriched the single-cell transcriptomic information for RCC, thereby providing new insights into the diagnosis and treatment of RCC.

show abstract

“…In the final oncological outcomes of Checkmate 214 after the long-term follow-up period, NIVO + IPI continued to demonstrate durable efficacy benefits compared with sunitinib [11]. Massari et al reported that the clinical benefit obtained by patients with mRCC who received immunotherapy combinations with a complete response (CR) rate was more than in those who received the TKI and ICI combination [12].…”

Section: Introductionmentioning

confidence: 99%

Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab

Iinuma

Enomoto

Kawada

et al. 2021

JCM

View full text Add to dashboard Cite

The aim of this study was to assess the utility of neutrophil-to-lymphocyte ratio (NLR), plate-let-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) as predictive biomarkers with oncological outcomes for metastatic renal cell carcinoma (mRCC) patients treated with nivolumab and ipilimumab (NIVO + IPI). We conducted a retrospective multicenter cohort study assessing patients with mRCC treated with NIVO + IPI at eight institutions in Japan. In this study, the follow-up period was median 14 months. The 1-year overall- and progression-free survival (PFS) rates were 89.1% and 63.1, respectively. The objective response rate (ORR) and disease control rate (DCR) were 41.9% and 81.4%, respectively. The 1-year PFS rates were 85.7% and 49.1% for NLR ≤ 2.8 and >2.8, respectively (p = 0.005), and 75.5% and 49.7% for PLR ≤ 215.6 and >215.6, respectively (p = 0.034). Regarding SII, the 1-year PFS rates were 90.0% and 54.8% when SII was ≤561.7 and >561.7, respectively (p = 0.023). Therefore, NLR, PLR, and SII levels in mRCC patients treated with NIVO + IPI may be useful in predicting oncological outcomes.

show abstract

Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials

Cited by 78 publications

References 18 publications

Gut Microbiota and Sunitinib-Induced Diarrhea in Metastatic Renal Cell Carcinoma: A Pilot Study

Gut Microbiota and Sunitinib-Induced Diarrhea in Metastatic Renal Cell Carcinoma: A Pilot Study

Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers

Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab

Contact Info

Product

Resources

About